Pharmaceutical India-based Zydus Cadila, a part of Cadila Healthcare, has submitted the New Drug Application (NDA) to the Drug Controller General of India for desidustat, an oral small molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for treatment of anemia in patients with chronic kidney disease (CKD) who are on or not on dialysis. 23 November 2021